Recently, CXCR1 and CXCR2 antagonist are used to treat human melanoma (18), lung (19), breast (20), and pancreatic cancer (21) growth by inhibiting tumor cell proliferation and suppression of angiogenesis and metastasis. This evidence concerns the gene CXCR1 and melanoma.